Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:IMNM NASDAQ:TRVI NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.99-1.6%$2.68$0.87▼$6.14$307.68M0.991.10 million shs986,435 shsIMNMImmunome$14.10-1.1%$10.65$5.15▼$15.13$1.24B1.941.86 million shs674,550 shsTRVITrevi Therapeutics$10.19+4.9%$8.25$2.36▼$10.31$1.18B0.741.95 million shs2.57 million shsWVEWAVE Life Sciences$7.89+1.3%$8.09$5.28▼$16.74$1.24B-1.372.08 million shs1.55 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-1.64%-2.61%+8.73%+91.67%-38.98%IMNMImmunome-1.05%+2.03%+53.09%+45.81%+16.05%TRVITrevi Therapeutics+4.94%+6.70%+23.52%+51.86%+220.44%WVEWAVE Life Sciences+1.28%+9.74%+13.20%+0.90%-9.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.99-1.6%$2.68$0.87▼$6.14$307.68M0.991.10 million shs986,435 shsIMNMImmunome$14.10-1.1%$10.65$5.15▼$15.13$1.24B1.941.86 million shs674,550 shsTRVITrevi Therapeutics$10.19+4.9%$8.25$2.36▼$10.31$1.18B0.741.95 million shs2.57 million shsWVEWAVE Life Sciences$7.89+1.3%$8.09$5.28▼$16.74$1.24B-1.372.08 million shs1.55 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-1.64%-2.61%+8.73%+91.67%-38.98%IMNMImmunome-1.05%+2.03%+53.09%+45.81%+16.05%TRVITrevi Therapeutics+4.94%+6.70%+23.52%+51.86%+220.44%WVEWAVE Life Sciences+1.28%+9.74%+13.20%+0.90%-9.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$4.1739.35% UpsideIMNMImmunome 2.82Moderate Buy$23.2064.54% UpsideTRVITrevi Therapeutics 2.89Moderate Buy$21.75113.44% UpsideWVEWAVE Life Sciences 2.81Moderate Buy$20.33157.71% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, TRVI, IMNM, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ALECAlectorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IMNMImmunomeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TRVITrevi TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025WVEWAVE Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ALECAlectorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMNMImmunomeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TRVITrevi TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025WVEWAVE Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025ALECAlectorBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/22/2025IMNMImmunomeThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.009/22/2025IMNMImmunomeThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M3.01N/AN/A$1.29 per share2.32IMNMImmunome$9.04M135.76N/AN/A$2.27 per share6.21TRVITrevi TherapeuticsN/AN/AN/AN/A$1.30 per shareN/AWVEWAVE Life Sciences$108.30M11.59N/AN/A$1.37 per share5.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)IMNMImmunome-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.42N/AN/AN/AN/A-41.44%-38.21%11/5/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest ALEC, TRVI, IMNM, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025N/AIMNMImmunome-$0.57N/AN/AN/A$0.73 millionN/A11/11/2025Q3 2025WVEWAVE Life Sciences-$0.30N/AN/AN/A$9.85 millionN/A11/5/2025Q3 2025ALECAlector-$0.40N/AN/AN/A$3.49 millionN/A11/5/2025Q3 2025TRVITrevi Therapeutics-$0.10N/AN/AN/AN/AN/A8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million8/7/2025Q2 2025TRVITrevi Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A8/6/2025Q2 2025IMNMImmunome-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78IMNMImmunomeN/A12.1312.13TRVITrevi TherapeuticsN/A22.4222.42WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%IMNMImmunome44.58%TRVITrevi Therapeutics95.76%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%IMNMImmunome7.69%TRVITrevi Therapeutics18.30%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableIMNMImmunome4087.04 million80.35 millionOptionableTRVITrevi Therapeutics20121.78 million99.49 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableALEC, TRVI, IMNM, and WVE HeadlinesRecent News About These CompaniesWave Life Sciences initiated with a Buy at Clear Street2 hours ago | msn.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from AnalystsOctober 14 at 2:15 AM | americanbankingnews.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 14 at 2:14 AM | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 5.3% - Here's What HappenedOctober 11, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 9.3% - Should You Buy?October 10, 2025 | marketbeat.comWave Life Sciences (WVE): A Valuation Deep Dive Following Pipeline Progress and Investor OptimismOctober 10, 2025 | finance.yahoo.comStrength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?October 10, 2025 | zacks.comWAVE Life Sciences' (WVE) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comWave Life Sciences (WVE) Receives a Buy from Leerink PartnersOctober 7, 2025 | theglobeandmail.comCanaccord Genuity Keeps Their Buy Rating on Wave Life Sciences (WVE)October 7, 2025 | theglobeandmail.comWAVE Life Sciences Ltd. $WVE Stake Raised by Platinum Investment Management Ltd.October 2, 2025 | marketbeat.comInvivyd appoints Wave Life Sciences CEO Paul Bolno to boardSeptember 25, 2025 | msn.comWave Life Sciences Highlights WVE-007 Obesity TreatmentSeptember 25, 2025 | msn.com50,300 Shares in WAVE Life Sciences Ltd. $WVE Acquired by Strs OhioSeptember 23, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 19, 2025 | marketbeat.com3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025September 18, 2025 | zacks.comWave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor ConferencesSeptember 18, 2025 | globenewswire.comWave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 StudySeptember 10, 2025 | finance.yahoo.comRaymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)September 9, 2025 | theglobeandmail.comWave Life Sciences Announces Positive Results for WVE-006 StudySeptember 8, 2025 | theglobeandmail.comB. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’September 6, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, TRVI, IMNM, and WVE Company DescriptionsAlector NASDAQ:ALEC$2.99 -0.05 (-1.64%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$2.98 -0.01 (-0.17%) As of 10/14/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Immunome NASDAQ:IMNM$14.10 -0.15 (-1.05%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$14.20 +0.10 (+0.70%) As of 10/14/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Trevi Therapeutics NASDAQ:TRVI$10.19 +0.48 (+4.94%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$10.11 -0.08 (-0.79%) As of 10/14/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.WAVE Life Sciences NASDAQ:WVE$7.89 +0.10 (+1.28%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$7.96 +0.07 (+0.87%) As of 10/14/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
